Arkolith/Insider Trading/CRSP/Form 4

Kulkarni Samarth

Chief Executive Officer, DirectorCRISPR Therapeutics AG (CRSP) · full profile →Form 4 · filed Mar 24, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$469K
Net Open-Market Flow
-$469K
Transactions
5
2 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 23, 2026Sell(S)10K$46.78$469K256K
Mar 20, 2026Option exercise(M)20K——266K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 20, 2026Option exercise(M)20K——39K
Mar 20, 2026Grant(A)82K—$082K
Mar 20, 2026Grant(A)114K—$0114K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-122272) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML